Who
Timothy L. Moore
Director
Company insider
Files Form 4 as: Director, BioLife Solutions; Director, Cerus; Chief Technical Officer, Allogene Therapeutics; Chief Operating Officer, Instil Bio; EVP, Technical Operations, Kite Pharma.
In numbers
- Trades disclosed
- 63
- Buys
- 3
- Sells
- 5
- Bought
- $32K
- Sold
- $3.4M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 15 Mar 2016
- Last trade
- 6 Oct 2026
- Last filed
- 8 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 8 Oct 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code D | —44,943 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —8,170 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —8,170 | filing |
| 3 Jun 2025filed 4 Jun 2025 | CERS CerusMedical Devices | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 18 Mar 2025filed 20 Mar 2025 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —6,876 | filing |
| 3 Feb 2025filed 5 Feb 2025 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Sold | $25K14,746 at $1.71 | filing |
| 5 Jun 2024filed 6 Jun 2024 | CERS CerusMedical Devices | SEC FORM 4 Code A | $200K40,000 at $5.00 | filing |
| 22 Apr 2024filed 24 Apr 2024 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code F | $60K17,360 at $3.47 | filing |
| 8 Mar 2024filed 12 Mar 2024 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —11,264 | filing |
| 25 Jan 2024filed 31 Jan 2024 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —341,515 at $0.00 | filing |
| 25 Jan 2024filed 31 Jan 2024 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —96,600 at $0.00 | filing |
| 1 Nov 2023filed 3 Nov 2023 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —495 | filing |
| 1 Oct 2023filed 10 Oct 2023 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —362 | filing |
| 7 Jun 2023filed 9 Jun 2023 | CERS CerusMedical Devices | SEC FORM 4 Code A | $200K40,000 at $5.00 | filing |
| 24 Apr 2023filed 26 Apr 2023 | ALLO Allogene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —831,024 at $0.00 | filing |
| 24 Apr 2023filed 26 Apr 2023 | ALLO Allogene TherapeuticsBiotechnology | SEC FORM 4 Code A | —186,219 at $0.00 | filing |
| 3 Jan 2023filed 18 Jan 2023 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —10,187 | filing |
| 6 Sep 2022filed 6 Sep 2022 | TIL Instil Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 1 Sep 2022filed 6 Sep 2022 | BioLife SolutionsMedical Devices | SEC FORM 4 Code A | —7,589 | filing |
| 1 Jun 2022filed 3 Jun 2022 | CERS Cerusoption or derivative · Medical Devices | SEC FORM 4 Code A | —39,866 | filing |
News
Head to Head Analysis: Keros Therapeutics (NASDAQ:KROS) & Allogene Therapeutics (NASDAQ:ALLO)ALLO · tickerreport.com · 24 Oct 2026Comparing eXoZymes (NASDAQ:EXOZ) and Allogene Therapeutics (NASDAQ:ALLO)ALLO · dailypolitical.com · 16 Oct 2026TransMedics Group (NASDAQ:TMDX) and Cerus (NASDAQ:CERS) Head-To-Head ContrastCERS · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Timothy L. Moore; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.